Tris Pharma, Inc.’s recent voluntarily recall of infants’ ibuprofen sold at retailers Walmart, CVS Pharmacy and Family Dollar, has expanded to include 3 additional lots of the product.
In December, the pharma maker voluntarily recalled 3 lots of Infants’ Ibuprofen Concentrated Oral Suspension, USP, 50 mg per 1.25 ml, because they potentially have higher concentrations of ibuprofen.
Related: Pharma makers recall 2 important drugs
Certain lots of CVS, Walmart, and Family Dollar private label infants’ ibuprofen were included in the December recall, while the new recall includes different lots of CVS private label infants’ ibuprofen as well as lots of Walmart’s Equate private label ibuprofen and Family Dollar’s Family Wellness private label product.
“There is a remote possibility that infants, who may be more susceptible to a higher potency level of drug…may be more vulnerable to permanent NSAID-associated renal injury,” the New Jersey pharma maker said in a statement.
The newly recalled lots include Walmart’s Equate brand of infants’ ibuprofen with expiration dates of 2/19, 4/19, and 8/19; CVS Health’s brand of infants’ ibuprofen with an expiration date of 8/19; and Family Dollar’s Family Wellness brand with an expiration date of 8/19.
Related: Blood pressure drug recall expands
Adverse effects could include nausea, vomiting, epigastric pain, or more rarely, diarrhea. Tinnitus, headache and gastrointestinal bleeding are also possible adverse effects. However, Tris Pharma has not received any reports of adverse events related to the recalled lots.
Consumers with questions about the recall can contact Tris Customer Service at 732-940-0358 or via email.
Read more: FDA warns maker of ingredient in huge heart drug recall
Iowa Expands PBM Legislation to Address Concerns of Independent Pharmacies
May 16th 2025A new law in Iowa, if signed by the governor, will mandate 100% pass-through of rebates, increased financial transparency, and a minimal payment for pharmacies. Critics say it will be the most costly mandate in the state’s history.
Read More
Is Arkansas’ New PBM Law the Right Path Forward for Reform? No One Knows Yet
May 9th 2025It could improve access to community pharmacies and lower prices. Or it will limit access to critical drugs and impact payers’ ability to contract for a broad range of services. Industry leaders are unsure about the impact of Arkansas’ law banning PBMs from owning pharmacies.
Read More